Fluidigm announced that Covance has selected Fluidigm’s technology and its immune profiling assay to develop immune profiling services.
Fluidigm (NASDAQ:FLDM) announced that Covance, the drug development business of LabCorp (NYSE:LH), has selected Fluidigm’s CyTOF technology and the Maxpar Direct Immune Profiling Assay to develop immune profiling services.
As quoted in the press release:
Setting an industry first, high-multiplex mass cytometry enables clinical researchers to simultaneously profile more than 50 cell surface and intracellular parameters in a single run. Ideal for use with panels comprising more than 20 parameters, mass cytometry simplifies high-parameter panel design by using non-overlapping metal isotope tags that can be easily distinguished in cells using CyTOF technology. Empowering clinical researchers to deeply profile cell phenotypes and function with robust reproducibility, mass cytometry has been used in more than 70 clinical trials and is trusted by academic medical centers, pharmaceutical companies and research consortia worldwide.